Pharmixon announces the award of innovation support towards its R&D projects from BPI (Banque publique d'investissement).
Pharmixon has launched a search for an Executive Chairman which is a top management team position. The successful individual will be leading the process of taking the company to the next stage of development and also be responsible to increase the visibility of the company and its programs. Interested individuals should email gs@pharmixon.com for a role description and to address informal enquiries. Applications should be submitted by 5pm CET of June 17th, 2022.
Pharmixon is pleased to announce filing of a novel intellectual property (patent) application with the USPTO in continuation of our previous IP filing in April 2019. This novel IP strengthens company’s IP position and contributes to the long-term goal to become a leading player in Onco-Channelopathies. Also to mention, the important contribution of our technical R&D partners (3A Laboratories, UK, Proteogenix and Eurofins, France) towards the development of strategic inventory steps detailed in the submitted filing.